OVID - OVID Stock Extends Rally: Jumps 50% in a Week

OVID stock continues to move higher for the fourth straight session and jumps another 10% this morning after Ovid Therapeutics’ (NASDAQ:OVID) product “OV101” won orphan drug designation by the European Commission.

Ovid Therapeutics, which is based out of New York, has been one of the bigger gainers in the biopharmaceutical space over the past week, and today, the company received significantly positive news again. In a new development, the company’s product OV101 has been awarded the coveted orphan drug designation by the European Commission, and it goes without saying that it is an ...